REGENERON PHARMACEUTICALS (REGN)       747  +10.77 (+1.46%)

747  +10.77 (+1.46%)

US75886F1075 - Common Stock

REGENERON PHARMACEUTICALS747

NASDAQ:REGN (11/28/2022, 12:16:30 PM)+10.77 (+1.46%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-03 2022-11-03/bmo Earnings (Next) 02-02 2023-02-02
Ins Owners 1.94% Inst Owners 85.6%
Market Cap 81.34B Shares 108.88M
PE 14.6 Fwd PE 16.96
Dividend Yield N/A Analysts 74.12
IPO 04-02 1991-04-02

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

REGN Daily chart

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 10,368 full-time employees. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Company Info

REGENERON PHARMACEUTICALS

777 Old Saw Mill River Road

Tarrytown NEW YORK 10591

P: 17813705000.0

CEO: Leonard S. Schleifer

Employees: 10368

Website: https://www.regeneron.com/

REGN News

News Imagean hour ago - ChartmillWhich S&P500 stocks are moving on Monday?

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

News Image3 days ago - Investor's Business DailyStock Market Investing Action Plan: What Part Of November Don't You Understand?

A turnabout month left the market sitting on some nice gains. The next week's data might determine whether those gains hold.

News Image3 days ago - Investor's Business DailyDexcom Leads 5 Stocks Near Buy Points

They combine strong technicals and generally sound fundamentals.

News Image6 days ago - Regeneron Pharmaceuticals, Inc.Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy...

News Image10 days ago - Market News VideoNotable Friday Option Activity: HES, REGN, DVNNews Image11 days ago - InvestorPlaceWhy Is CytomX Therapeutics (CTMX) Stock Up 29% Today?

CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN).

REGN Twits

Here you can normally see the latest stock twits on REGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example